Investing
Also: Truepill to expand digital pharmacy business with $25 million Series B; Nucleai's precision oncology platform gains $6.5 million from Debiopharm.
Like its competitors, the telehealth provider highlighted a major increase in business since COVID-19.
Telehealth and digital behavioral health were two of the most popular investment areas.
Despite the uncertainty of COVID-19, funding deals during the last three months were generally on par with those of Q1 2020 and Q2 2019.
Also: NexHealth's $15 million Series A, Avive Solutions' $7 million raise and Cyclica's $16.9 million Series B.
This latest contribution was led by Mubadala Capital and Bpifrance.
Alphabet, General Catalyst, Kholsa Ventures, Lakestar, Thrive Capital and Baillie Gifford participated in this round.
The company also announced a $5.1 million seed funding led by Forerunner Ventures.